Overview
- Revenue rose to $5.07 billion, beating consensus estimates of about $4.97 billion.
- Adjusted earnings were $0.75 per share versus expectations of $0.71, with net income of $755 million or $0.51 per share on a GAAP basis.
- Cardiovascular sales reached $3.34 billion, exceeding forecasts of $3.27 billion as procedure volumes stayed elevated.
- Management lifted full-year 2025 adjusted EPS guidance to $3.02–$3.04 and projected fourth-quarter EPS of $0.77–$0.79.
- The company moved to buy the remaining equity in Nalu Medical for about $533 million in cash and now projects a full-year tariff headwind of roughly $100 million, down from $200 million.